Public Company

Alterity Therapeutics Limited


Alterity Therapeutics is a clinical-stage biotechnology company focused on broad drug discovery for people living with neurodegenerative diseases. The company’s discovery platform generates patentable chemicals to intervene in disease processes. ATH434 is the company’s lead asset that has potential to treat multiple different forms of Parkinsonian disorders.


Founded 1997
Type Public
Location Melbourne, Victoria, Australia


ATHE $3.94 3.28% $0.13

Latest News

Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year? Jan 20, 2023 Zacks Investment Research Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.
5 Most Expensive Health Care Stocks You Should Worry About Jan 12, 2023 Benzinga The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator,...
Why DraftKings Shares Are Trading Lower By 5%; Here Are 24 Stocks Moving Premarket Nov 28, 2022 Benzinga Gainers Talkspace, Inc. (NASDAQ: TALK) shares rose 48.3% to $0.89 in pre-market trading. Talkspace recently named Jon Cohen as CEO. Ltd. (NASDAQ: TBLA) shares...
Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket Sep 20, 2022 Benzinga Gainers BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) rose 58.2% to $8.70 in pre-market trading. BYND Cannasoft shares jumped over 32% on Monday after the company...
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 Aug 03, 2022 Benzinga Upgrades Bernstein upgraded the previous rating for Cognex Corp (NASDAQ:CGNX) from Market Perform to Outperform. In the second quarter, Cognex showed an EPS of $0.41,...